Biogen agreed to buy RayThera in a deal valued at up to $1 billion, aiming to deepen its immunology pipeline with early-stage small-molecule assets. The acquisition gives Biogen a portfolio of candidates described as anti-inflammatory, including a lead program expected to enter Phase I in early Q3 2026, according to company statements.